PCN66 Cost-Effectiveness of Denosumab Versus Zoledronic Acid for Skeletal-Related Event (SRE) Reduction in Bone-Metastatic Prostate Cancer (mPC) in the UK
Value in Health - United Kingdom
doi 10.1016/j.jval.2012.08.2106
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2012
Authors
Publisher
Elsevier BV